Will anti-HCV measures unveiled after mass infection be sufficient?
By Park Gi-taek
From the end of 2015 to 2016, mass infections of hepatitis C occurred at three hospitals. Before these incidents, chronic hepatitis C had not been a major disease in Korea. Around the same time, new medicines with sharply improved cure rates were released, but they remained largely unknown because of high prices and the low attack rate of hepatitis C in Korea.
Professor Cheon Dae-won of Hanyang University College of Medicine explains about the influence the mass infections of Hepatitis C last year has exerted on the Korean society and the new treatment trends, during a recent interview with Korea Biomedical Review at his office
Why do you think the prevalence of Hepatitis B is decreasing while hepatitis C is increasing? Can the prevalence of HCV be due to the emergence of hidden patients amid the growth of awareness and change of policy?
A: Personally, I think the prevalence rate of Hepatitis C itself is rising. It is the most prevalent type of hepatitis in most of the developed countries, including the United States and Japan.......
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- Treating Elderly HCV Patients
- FibroScan® Understanding The Results
- Staging Cirrhosis
- Is There A Natural Way To Improve Liver Fibrosis?